November 18th, 2026Low CRC Incidence Found After Endoscopic Mucosal ResectionCRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.Read more
November 18th, 2026FDA Approves Obinutuzumab as First Therapy for Membranous NephropathyObinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.Read more
November 18th, 2026Complicated UTI Care Strained by Unclear Goals, Access GapsInfectious disease and urology clinicians described unclear treatment goals, infusion limits, and access barriers for newer UTI agents.Read more
November 18th, 2026Aficamten Reduces LV Mass, Wall Thickness in Nonobstructive HCMNew ACACIA-HCM analyses at HCMS 2026 add imaging and quality-of-life data as Cytokinetics readies an FDA filing in nonobstructive HCM.Read more
November 18th, 2026FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast CancerAn oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer. Read more
November 18th, 2026Hepatitis B Screening Gaps Persist as Functional Cure Option ArrivesNew York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.Read more
November 18th, 2026Dazodalibep Shows Phase 3 Benefit in Sjögren Disease Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.Read more
November 18th, 2026IgA Nephropathy, FSGS Care Needs Coordinators, Not Just New DrugsSan Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.Read more